Table of Contents Table of Contents
Previous Page  274 / 280 Next Page
Show Menu
Previous Page 274 / 280 Next Page
Page Background

The Buckingham Institute of Translational Medicine

The University of Buckingham


he Buckingham Institute of Translational Medicine is based within the Clore Laboratory and is an internationally recognised

research group led by Professors Mike Cawthorne and Jon Arch, researchers with a track record in drug discovery, including

beta3-adrenoceptor agonists for obesity, orexin and MCH-antagonists, and the insulin sensitiser drug rosiglitazone. Mike

Cawthorne was awarded the 2001 Society for Medicines Research Award for drug discovery in recognition of his work on the

discovery of rosiglitazone.

Our focus is encompassed by three research themes which highlight our combined basic research, drug discovery and clinical

expertise. The aim of our preclinical research is to inform drug development and enhance underlying biological understanding.

Through interaction with the medical school and our longstanding academic, clinical and pharmaceutical collaborations we are

translating our key research themes into clinical studies and ultimately therapeutics.


Diabetes, obesity and metabolic disease;


Dermatology; and


Biomedical informatics.

The Institute of Translational Medicine brings together drug discovery expertise, including chemoinformatics; basic science studies in

the areas of obesity, diabetes and metabolic disease; and dermatology studies, including cancer, bioinformatics and bioimaging.

The institute’s staff has more than 100 years of drug discovery experience in industry and has been at the forefront of drug discovery

in the metabolic disease area for decades.

The university has developed a medical school and the first students entered the MBChB programme in January 2015.